Bioasis Technologies Inc. Announces Stock Option Grants
Bioasis Technologies Inc. Announces Stock Option Grants
BTI-CRPNEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 platform for delivering therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, today announced that it has granted stock options to acquire a total of 2,011,000 common shares effective August 8, 2022 at a price of $0.13 per share to directors and officers of the Company and an investor relations consultant. All of the options expire five years from the date of the grant and are governed by the terms of the company's stock option plan. The options are being issued as part of annual remuneration.
康涅狄格州紐黑文，2022年8月8日(Global Newswire)--BiOasis Technologies Inc..(多倫多證券交易所股票代碼：BTI；OTCQB：BIOAF)，(公司或生物綠洲)，一家多資產罕見和孤兒疾病生物製藥公司，基於表皮生長因子和差異化、專有的xB開發臨牀階段計劃3在高度未得到滿足的醫療需求地區提供跨越血腦屏障(BBB)的治療藥物和治療中樞神經系統(CNS)疾病的平臺, 今天宣佈，已向公司董事和高級管理人員以及一名投資者關係顧問授予股票期權，從2022年8月8日起以每股0.13美元的價格收購總計2,011,000股普通股。所有期權自授予之日起五年到期，並受該公司股票期權計劃的條款管轄。這些期權是作為年度薪酬的一部分發布的。
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board
代表BiOasis Technologies Inc.董事會。
Deborah Rathjen，博士，董事會執行主席
Follow on:
Facebook
Instagram
LinkedIn
Twitter
後續內容：
Facebook
Instagram
LinkedIn
推特
BTI-CRP
BTI-CRP
About Bioasis
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit .
關於BiOASIS
BiOasis Technologies Inc.是一家多資產罕見和孤兒疾病生物製藥公司，開發基於表皮生長因子和xB的臨牀分期計劃3™Platform是一項專利技術，用於通過血腦屏障提供治療藥物，並在高度未得到滿足的醫療需求領域治療中樞神經系統疾病。通過血腦屏障提供治療藥物代表着治療神經疾病的最後前沿。BiOASIS的內部開發計劃旨在為與大腦相關的疾病和障礙開發對症和疾病修改治療。欲瞭解更多有關該公司的信息，請訪問。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任
Contacts:
Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
deborah@bioasis.us
203-533-7082
聯繫人：
黛博拉·拉特金博士，董事會執行主席兼首席執行官
郵箱：deborah@biasis.us
203-533-7082
Investor Contact:
Graeme Dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989
投資者聯繫方式：
格雷姆·迪克
科爾韋爾資本公司
郵箱：graeme@colwell capal.com
403-561-8989
譯文內容由第三人軟體翻譯。
